---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-25-016767"
form_type: "8-K"
ticker: "RGBP"
cik: "0001589150"
company_name: "Regen BioPharma Inc"
filed_at: "2025-10-03T23:59:59+00:00"
generated_at: "2026-05-17T04:45:08.040689+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Regen BioPharma issues 40M shares to CEO and consultant for Phase I trial; shares vest on trial success

## Summary
- Issued 20M shares to CEO David Koos for services in planned Phase I trial of HemaXellerate; shares vest upon trial completion.
- Issued 20M shares to consultant Dr. Harry Lander for same purpose; same vesting condition.
- Total outstanding shares jump to 79,374,704 as of Oct 3, 2025, reflecting ~100% dilution from these grants.
- Phase I trial targets drug-refractory aplastic anemia using autologous stromal vascular fraction from adipose tissue.
- Shares are restricted and unregistered; vest only upon successful trial completion, otherwise forfeited.

## SEC filing metadata
- accession: 0001493152-25-016767
- form_type: 8-K
- ticker: RGBP
- cik: 0001589150
- company_name: Regen BioPharma Inc
- filed_at: 2025-10-03T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1589150/000149315225016767/0001493152-25-016767-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1589150/000149315225016767/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-25-016767
- JSON: https://secwatch.observer/filing/0001493152-25-016767.json
- Plain text: https://secwatch.observer/filing/0001493152-25-016767.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.